American Society of Hematology (ASH)

The American Society of Hematology (ASH) is a professional organization representing hematologists. It was founded in 1958. Its annual meeting is held in December of every year and has attracted more than 30,000 attendees. The society publishes the medical journal Blood, the most cited peer-reviewed publication in the field, which is available weekly in print and online, as well as the newly launched, online, peer-reviewed open-access journal, Blood Advances.

Leslie Lauersdorf provides an overview of some of the most exciting clinical developments in multiple myeloma based on data presented at ASH 2019. Read More ›

Novel Myeloma Regimen Improves Outcomes in Systemic AL Amyloidosis

ASH 2019 – Multiple Myeloma

In systemic amyloid light chain (AL) amyloidosis, treatment with ixazomib/dexamethasone proved more beneficial than treatment of physician’s choice, although hematologic response was not improved. Read More ›

Selinexor + Pomalidomide + Dexamethasone Combination Leads to Promising Response Rates in Relapsed or Refractory Multiple Myeloma

ASH 2019 – Multiple Myeloma

Selinexor, pomalidomide, and dexamethasone led to high response rates in patients with multiple myeloma who were refractory to lenalidomide and had not been previously treated with pomalidomide. Read More ›

Daratumumab + Lenalidomide + Dexamethasone Combination Continues to Improve Progression-Free Survival in Relapsed or Refractory Multiple Myeloma

ASH 2019 – Multiple Myeloma

After more than 4 years of median follow-up, treatment with daratumumab, lenalidomide, and dexamethasone continues to improve progression-free survival compared with lenalidomide and dexamethasone alone in relapsed/refractory multiple myeloma, with deep and durable responses. Read More ›

Clinical Trial Discontinuation Significantly Lower in Patients Treated with Daratumumab

ASH 2019 – Multiple Myeloma

Despite safety concerns related to daratumumab, a meta-analysis of 5 large randomized controlled trials showed no significant increase in treatment delays, trial discontinuation, or treatment-related deaths in patients with untreated or relapsed/refractory multiple myeloma who received the drug. Read More ›

Ibrutinib 7-Year Follow-Up Data in First-Line and Relapsed/Refractory Patients with CLL/SLL

ASH 2018 – CLL

After 7 years of follow-up, sustained progression-free survival and overall survival rates were seen with ibrutinib, as well as stable or improved complete response rates over time. Read More ›

Prognostic Testing and Treatment Approaches in Patients with CLL: Interim Analysis of the informCLL Real-World Registry

ASH 2018, ASH 2018 – CLL

informCLL registry analysis revealed that prognostic testing patterns in the real-world setting remain suboptimal despite inclusion in National Comprehensive Cancer Network and International Workshop on Chronic Lymphocytic Leukemia guidelines. Read More ›

Cost-Effectiveness Comparison of Ibrutinib, Chemotherapy, and Chemoimmunotherapy in First-Line Treatment of CLL

ASH 2018 – CLL

Although ibrutinib is generally cost-effective in first-line use compared with chemotherapy and chemoimmunotherapy, a subset of ibrutinib-treated patients with cardiovascular events had a mitigating impact on the total cost of care. Read More ›

ECOG-ACRIN Cancer Research Group: Phase 3 Study of Ibrutinib-Based Therapy in Untreated Younger Patients with CLL

ASH 2018 – CLL

In a phase 3 study, the combination of ibrutinib and rituximab provided superior progression-free survival and overall survival relative to the combination of fludarabine, cyclophosphamide, and rituximab for younger patients with previously untreated chronic lymphocytic leukemia (CLL) Read More ›

Acalabrutinib in Patients with Relapsed/Refractory and High-Risk, Treatment-Naïve CLL

ASH 2018 – CLL

Researchers evaluating the Bruton’s tyrosine kinase inhibitor acalabrutinib monotherapy in relapsed/refractory and high-risk, treatment-naïve chronic lymphocytic leukemia (CLL) patients reported high response rates and an acceptable safety profile. Read More ›

American Society of Hematology (ASH)

Page 21 of 44